{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:55:38Z","timestamp":1782298538569,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clbc.2025.06.008","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:29:15Z","timestamp":1751426955000},"page":"e1011-e1022.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Thirty-Five-Year Follow-Up Real-World Data Revealed the Efficacy of Autologous Formalin-Fixed Tumor Vaccine on Metastatic Breast Cancer\u2014A Target Trial Emulation"],"prefix":"10.1016","volume":"25","author":[{"given":"Fumito","family":"Kuranishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Tagashira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michimasa","family":"Yuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichirou","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Makihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shungo","family":"Nakagou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2025.06.008_bib0001","series-title":"Breast cancer treatment guidelines 2022, Part 1: Treatment, Chapter V: Metastatic and recurrent breast cancer, section 2","year":"2022"},{"key":"10.1016\/j.clbc.2025.06.008_bib0002","doi-asserted-by":"crossref","first-page":"100114","DOI":"10.1016\/j.esmoop.2021.100114","article-title":"Evolution of overall survival and receipt of new therapies by subtype among 20446 metastatic breast cancer patients in the 2008-2017 ESME cohort","volume":"6","author":"Grinda","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.clbc.2025.06.008_bib0003","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/1078-0432.CCR-03-0071","article-title":"Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma","volume":"10","author":"Kuang","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2025.06.008_bib0004","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/j.1349-7006.2007.00518.x","article-title":"Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients","volume":"98","author":"Ishikawa","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clbc.2025.06.008_bib0005","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2176\/nmc.51.319","article-title":"Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports -","volume":"51","author":"Sakamoto","year":"2011","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"10.1016\/j.clbc.2025.06.008_bib0006","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3171\/2011.4.JNS10377","article-title":"Phase I \/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma","volume":"115","author":"Muragaki","year":"2011","journal-title":"J Neurosurg"},{"key":"10.1016\/j.clbc.2025.06.008_bib0007","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1477-7819-10-144","article-title":"Autologous formalin-fixed tumor vaccine suppressed re-recurrence of HCV-related hepatocellular carcinoma following 29 unsuccessful treatments with extensive conventional therapy: a case report","volume":"10","author":"Inui","year":"2012","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.clbc.2025.06.008_bib0008","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/ccr3.353","article-title":"Recurrent peritoneal serous carcinoma that was unmanageable with paclitaxel\u2013carboplatin therapy responded to autologous formalin-fixed tumor vaccine","volume":"3","author":"Chen","year":"2015","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.clbc.2025.06.008_bib0009","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/ccr3.1179","article-title":"Complete remission of chemo-refractory multiple-metastatic upper tract urothelial carcinoma by autologous formalin-fixed tumor vaccine","volume":"5","author":"Miyoshi","year":"2017","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.clbc.2025.06.008_bib0010","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12957-017-1245-x","article-title":"Long-lasting complete response status of advanced stage IV gall bladder cancer and colon cancer after combined treatment including autologous formalin-fixed tumor vaccine: two case reports","volume":"15","author":"Imaoka","year":"2017","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.clbc.2025.06.008_bib0011","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1477-7819-9-96","article-title":"Long-term survivor of relapsed MFH on the thigh treated with autologous formalin-fixed tumor vaccine (AFTV) combined with limb-sparing surgery and radiotherapy","volume":"9","author":"Todoroki","year":"2011","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.clbc.2025.06.008_bib0012","doi-asserted-by":"crossref","first-page":"e7513","DOI":"10.1002\/ccr3.7513","article-title":"Successful monotherapy with autologous formalin-fixed tumor vaccine for a stage IV uterine cancer patient who rejected rational chemotherapy and immune checkpoint inhibitor treatment","volume":"11","author":"Fukuda","year":"2023","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.clbc.2025.06.008_bib0013","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1477-7819-11-127","article-title":"Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report","volume":"11","author":"Kuranishi","year":"2013","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.clbc.2025.06.008_bib0014","article-title":"Rate of clinical complete response for 1 year or more in bone-metastatic breast cancer after comprehensive treatments including autologous formalin-fixed tumor vaccine","volume":"4879406","author":"Kuranishi","year":"2018","journal-title":"Int J Breast Cancer"},{"key":"10.1016\/j.clbc.2025.06.008_bib0015","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/annonc\/mdg348","article-title":"Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients","volume":"14","author":"Koizumi","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2025.06.008_bib0016","article-title":"Target trial emulation: applying principles of randomized trials to observational studies","volume":"378","author":"Matthews","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.clbc.2025.06.008_bib0017","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR'for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clbc.2025.06.008_bib0018","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"10390","key":"10.1016\/j.clbc.2025.06.008_bib0019","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andre","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2025.06.008_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03269-z","article-title":"Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial","author":"Xu","year":"2024","journal-title":"Nature Med"},{"key":"10.1016\/j.clbc.2025.06.008_bib0021","first-page":"1","article-title":"Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer - the Phase III MECCA Trial","volume":"00","author":"Hong","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.06.008_bib0022","unstructured":"National Cancer Center Japan. Cancer information service, Cancer statistics by type, breast cancer, 2024. Available at: https:\/\/hbcr-survival.ganjoho.jp\/graph?year=2014-2015&elapsed=5&type=c09#h-title."},{"key":"10.1016\/j.clbc.2025.06.008_bib0023","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12967-023-04017-6","article-title":"Immunogenic cell death in cancer: concept and therapeutic implications","volume":"21","author":"Galluzzi","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.clbc.2025.06.008_bib0024","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrclinonc.2016.30","article-title":"Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?","volume":"13","author":"Bernstein","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clbc.2025.06.008_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.clbc.2025.06.008_bib0026","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.clbc.2025.06.008_bib0027","doi-asserted-by":"crossref","first-page":"136","DOI":"10.21037\/tcr.2017.01.32","article-title":"The abscopal effect induced by in situ-irradiated peripheral tumor cells in a murine GL261 brain tumor model","volume":"6","author":"Zenkoh","year":"2017","journal-title":"Translational Cancer Res"},{"key":"10.1016\/j.clbc.2025.06.008_bib0028","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: a paradigm shift","volume":"105","author":"Formenti","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2025.06.008_bib0029","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.06.008_bib0030","unstructured":"Opdivo, European Medicines Agency, Reference Number:EMA\/217560\/2024, 2024. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/opdivo."},{"issue":"1","key":"10.1016\/j.clbc.2025.06.008_bib0031","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41523-023-00579-2","article-title":"Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer","volume":"8","author":"Fabi","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2025.06.008_bib0032","article-title":"Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer","volume":"5","author":"Rached","year":"2024","journal-title":"ESMO RWD and Digital Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2025.06.008_bib0033","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1007\/s12020-024-03859-4","article-title":"Immune checkpoint inhibitors-related endocrinopathies exhibit increased severity in breast cancer patients: a real-world study","volume":"85","author":"Gao","year":"2024","journal-title":"Endocrine"},{"issue":"Suppl 8","key":"10.1016\/j.clbc.2025.06.008_bib0034","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I","article-title":"Mechanisms of bone metastasis","volume":"80","author":"Mundy","year":"1997","journal-title":"Cancer"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925001788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925001788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:57:38Z","timestamp":1763751458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820925001788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1526820925001788"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.06.008","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thirty-Five-Year Follow-Up Real-World Data Revealed the Efficacy of Autologous Formalin-Fixed Tumor Vaccine on Metastatic Breast Cancer\u2014A Target Trial Emulation","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}